Alnylam Pharmaceuticals (BMV:ALNY *) - Stock Price, News & Analysis

ALNY * Stock Overview

A biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More details

ALNY * fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 40.8% below our estimate of its fair value

Earnings are forecast to grow 70.66% per year

Earnings have grown 12.1% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Alnylam Pharmaceuticals, Inc. Competitors

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Natera

NasdaqGS:NTRA

US$21.4b

BeiGene

NasdaqGS:BGNE

US$19.9b

argenx

ENXTBR:ARGX

€33.4b

Price History & Performance

Summary of all time highs, changes and price drops for Alnylam Pharmaceuticals
Historical stock prices
Current Share Price	US$4,900.00
52 Week High	US$5,899.69
52 Week Low	US$2,453.00
Beta	0.39
11 Month Change	-16.94%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	30.46%
5 Year Change	n/a
Change since IPO	261.42%

Recent updates

Shareholder Returns

	ALNY *	MX Biotechs	MX Market
7D	-16.9%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how ALNY * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how ALNY * performed against the MX Market.

Price Volatility

Is ALNY *'s price volatile compared to industry and market?
ALNY * volatility
ALNY * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: ALNY *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine ALNY *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2002	2,100	Yvonne Greenstreet	www.alnylam.com

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.

Alnylam Pharmaceuticals, Inc. Fundamentals Summary

How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap?
ALNY * fundamental statistics
Market cap	Mex$651.47b
Earnings (TTM)	-Mex$6.75b
Revenue (TTM)	Mex$42.53b

15.3x

P/S Ratio

-96.6x

P/E Ratio

Is ALNY * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALNY * income statement (TTM)
Revenue	US$2.09b
Cost of Revenue	US$306.41m
Gross Profit	US$1.79b
Other Expenses	US$2.12b
Earnings	-US$332.26m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.58
Gross Margin	85.37%
Net Profit Margin	-15.86%
Debt/Equity Ratio	7,566.4%

How did ALNY * perform over the long term?

See historical performance and comparison

ALNY * Stock Overview

Rewards

Risk Analysis

Alnylam Pharmaceuticals, Inc. Competitors

NasdaqGS:HZNP

US$26.6b

NasdaqGS:NTRA

US$21.4b

NasdaqGS:BGNE

US$19.9b

ENXTBR:ARGX

€33.4b

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: US$0.87 loss per share (vs US$1.18 profit in 3Q 2023)

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Recent updates

Third quarter 2024 earnings released: US$0.87 loss per share (vs US$1.18 profit in 3Q 2023)

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$2.21 loss in 2Q 2023)

Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

CEO & Director recently sold Mex$35m worth of stock

Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

CEO & Director recently sold Mex$18m worth of stock

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Forecast to breakeven in 2026

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

President recently sold Mex$13m worth of stock

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023

CEO & Director recently sold Mex$27m worth of stock

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. Announces Board Changes

Alnylam Pharmaceuticals, Inc. Submits CTA Application for Aln-Khk, an Investigational RNAi therapeutic for the Treatment of Type 2 Diabetes

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration for ONPATTRO® (Patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Alnylam Pharmaceuticals, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Presents Additional Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy At Heart Failure Society of America Annual Meeting

Alnylam Pharmaceuticals, Inc. Announces Executive Appointments

Alnylam Pharmaceuticals, Inc. Receives Approval in Europe for AMVUTTRA (Vutrisiran) for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals Announces Preliminary Phase 1 Data Supporting the Clinical Advancement of ALN-HSD

Alnylam Presents Positive Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

Alnylam Appoints Elliott Sigal, M.D., Ph.D., to Board of Directors

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$1.15 loss per share (vs US$1.61 loss in 2Q 2021)

Alnylam Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. to Report Q2, 2022 Results on Jul 28, 2022

No longer forecast to breakeven

Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of Iga Nephropathy